• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Acrivon Therapeutics Inc.

    4/25/25 8:32:08 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRV alert in real time by email
    DEFA14A
    0001781174falseDEFA14A00017811742024-01-012024-12-31

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE
    14A
    (Rule 14a-101)

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material under §240.14a-12

     

     

    img244011982_0.jpg

     

    Acrivon Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)
     

    (Name of Person(s) Filing Proxy Statement, if other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

    img244011982_1.jpg

     

    Acrivon therapeutics p.o. Box 8016, cary, nc 27512-9903 your vote matters! Acrivon therapeutics, inc. Annual meeting of stockholders friday, june 13, 2025 11:00 am, eastern time annual meeting to be held virtually via the internet - please visit www.proxypush.com/acrv for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/acrv for a convenient way to view proxy materials, vote, and obtain directions to attend the meeting go to www.proxydocs.com/acrv to vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under united states securities and exchange commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before june 3, 2025. Meeting materials: notice of meeting and proxy statement & annual report on form 10-k important notice regarding the availability of proxy materials for the stockholders meeting to be held on june 13, 2025 for stockholders of record as of april 21, 2025 to order paper materials, use one of the following methods. To receive paper materials, you must make this request on or before june 3, 2025. Internet: www.investorelections.com/acrv call: 1-866-648-8133 email: [email protected] * if requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material. Your control number have the 12 digit control number located in the box above available when you access the website and follow the instructions. See reverse for full agenda copyright © 2025 betanxt, inc. Or its affiliates. All rights reserved


    img244011982_2.jpg

     

    Acrivon therapeutics acrivon therapeutics, inc.annual meeting of stockholders the board of directors recommends a vote: for all director nominees and for proposal 2 proposal 1. Election of class iii directors 1.01 peter blume-jensen, m.d., ph.d.1.02 derek dirocco, ph.d. 1.03 santhosh palani, ph.d., c.f.a..2. To ratify the appointment of pricewaterhousecoopers llp as the company's independent registered public accounting firm for the fiscal year ending december 31, 2025.3.the transaction of such other business as may properly come before the meeting.


    Get the next $ACRV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRV

    DatePrice TargetRatingAnalyst
    5/5/2025$6.00Overweight
    Piper Sandler
    1/31/2025Overweight
    KeyBanc Capital Markets
    9/16/2024$16.00Neutral → Buy
    Ladenburg Thalmann
    4/29/2024Buy → Neutral
    Ladenburg Thalmann
    3/1/2024$14.00Mkt Outperform
    JMP Securities
    12/15/2023$17.00 → $12.00Buy
    Jefferies
    10/5/2023Buy
    Maxim Group
    6/2/2023$25.00Outperform
    Oppenheimer
    More analyst ratings

    $ACRV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Blume-Jensen Peter bought $82,124 worth of shares (49,000 units at $1.68) (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:02:48 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Levy Adam D. bought $14,999 worth of shares (8,832 units at $1.70), increasing direct ownership by 73% to 20,983 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:01:38 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Devroe Eric bought $17,218 worth of shares (10,000 units at $1.72), increasing direct ownership by 15% to 75,308 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/15/26 4:38:05 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    SEC Filings

    View All

    Acrivon Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)

    1/8/26 9:00:32 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)

    1/8/26 7:30:25 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Acrivon Therapeutics Inc.

    SCHEDULE 13G - Acrivon Therapeutics, Inc. (0001781174) (Subject)

    11/21/25 5:36:58 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Acrivon Therapeutics with a new price target

    Piper Sandler resumed coverage of Acrivon Therapeutics with a rating of Overweight and set a new price target of $6.00

    5/5/25 8:30:14 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Acrivon Therapeutics

    KeyBanc Capital Markets initiated coverage of Acrivon Therapeutics with a rating of Overweight

    1/31/25 8:29:16 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00

    9/16/24 7:17:32 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Miller Mary covered exercise/tax liability with 659 shares, decreasing direct ownership by 2% to 33,896 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/21/26 4:02:10 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Blume-Jensen Peter bought $82,124 worth of shares (49,000 units at $1.68) (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:02:48 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Levy Adam D. bought $14,999 worth of shares (8,832 units at $1.70), increasing direct ownership by 73% to 20,983 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:01:38 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC., Jan. 28, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – As the global oncology clinical trials market surges toward a projected $25.61 billion valuation by 2035[1], a structural rotation is favoring 'registration-ready' platforms that demonstrate exceptional efficacy and pivotal-trial alignment with 2026's evolving FDA regulatory frameworks[2]. Investors are increasingly prioritizing late-stage and newly commercial companies poised for rapid maturation as sector fundamentals strengthen. This structural shift creates a window for Oncolytics Biotech Inc. (NASDAQ:ONCY), BioNTech (NASDAQ:BNTX), MAIA Biotechnology (NYSE-A: MAIA)

    1/28/26 9:15:00 AM ET
    $ACRV
    $BNTX
    $IBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

    WATERTOWN, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced a presentation at the upcoming ESGO 27th Annual Congress, being held in Copenhagen, Denmark, February 26-28, 2026. "We are very excited that Dr. Konstantinopoulos will be

    1/23/26 8:11:33 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

    Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low d

    1/8/26 7:30:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Acrivon Therapeutics Inc.

    SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

    7/10/24 8:34:52 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acrivon Therapeutics Inc.

    SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

    7/10/24 8:29:53 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Acrivon Therapeutics Inc. (Amendment)

    SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

    4/15/24 8:21:55 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Leadership Updates

    Live Leadership Updates

    View All

    Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

    Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types WATERTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acriv

    4/7/25 4:05:00 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

    WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided business highlights. "On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year

    3/28/24 8:00:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

    WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors. "Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precisi

    3/4/24 8:00:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Financials

    Live finance-specific insights

    View All

    Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

    Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low d

    1/8/26 7:30:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

    WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a press release at 7:30 a.m. ET, and conference call and webcast at 8:30 a.m. ET, both on Thu

    1/6/26 7:30:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

    WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a conference call and webcast in January 2026. Topics will include: Updated interim ACR-368

    12/17/25 9:34:04 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care